New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology

Antonio Bellasi, Mario Cozzolino, Fabio Malberti, Giovanni Cancarini, Ciro Esposito, Carlo Maria Guastoni, Patrizia Ondei, Giuseppe Pontoriero, Ugo Teatini, Giuseppe Vezzoli, Marzia Pasquali, Piergiorgio Messa, Francesco Locatelli

Research output: Contribution to journalArticlepeer-review

Abstract

Bone mineral abnormalities (defined as Chronic Kidney Disease Mineral Bone Disorder; CKD-MBD) are prevalent and associated with a substantial risk burden and poor prognosis in CKD population. Several lines of evidence support the notion that a large proportion of patients receiving maintenance dialysis experience a suboptimal biochemical control of CKD-MBD. Although no study has ever demonstrated conclusively that CKD-MBD control is associated with improved survival, an expanding therapeutic armamentarium is available to correct bone mineral abnormalities. In this position paper of Lombardy Nephrologists, a summary of the state of art of CKD-MBD as well as a summary of the unmet clinical needs will be provided. Furthermore, this position paper will focus on the potential and drawbacks of a new injectable calcimimetic, etelcalcetide, a drug available in Italy since few months ago.

Original languageEnglish
Pages (from-to)211-221
JournalJournal of Nephrology
Volume33
Issue number2
DOIs
Publication statusPublished - 2020

Keywords

  • Cinacalcet
  • CKD-MBD
  • Etelcalcetide
  • PTH
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology'. Together they form a unique fingerprint.

Cite this